Henlius Biopharmaceuticals

Executive Summary

Henlius Biopharmaceuticals is a leading Chinese biopharmaceutical company specializing in the development and commercialization of high-quality monoclonal antibodies and biosimilars. Founded in 2010 and headquartered in Shanghai, the company has established a robust product portfolio primarily targeting oncology and immunology. Henlius has successfully launched several products in China, including HLX01 (rituximab biosimilar) and HLX02 (trastuzumab biosimilar), which have gained significant market share. The company is now aggressively expanding its international footprint, with product approvals in emerging markets and filings in the EU and US. Henlius aims to provide affordable biologic therapies to a global patient population, leveraging its vertically integrated manufacturing capabilities and strong R&D pipeline. Despite intense competition in the biosimilar space, Henlius differentiates itself through cost-efficiency, speed to market, and a focus on high-value targets. In recent years, Henlius has achieved several milestones, including the approval of HLX03 (adalimumab biosimilar) in China and the submission of its first biologic license application (BLA) to the FDA for HLX02. The company continues to advance its novel biologics pipeline, with candidates such as HLX22 (anti-HER2) and HLX10 (anti-PD-1) in late-stage clinical trials. Henlius also benefits from a strong partnership network, including a collaboration with Accord Healthcare for global commercialization. However, the company faces risks such as pricing pressures, regulatory uncertainties, and the need for substantial investment in international market access. Overall, Henlius is well-positioned for steady growth, driven by its biosimilar portfolio and expanding global presence.

Upcoming Catalysts (preview)

• Q3 2026FDA approval decision for HLX02 (trastuzumab biosimilar)75% success
• Q2 2026China NMPA approval for HLX10 (anti-PD-1) in first-line NSCLC80% success
• TBDPartnership or licensing deal for HLX22 (anti-HER2) in Asia60% success